Digipath
Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Social, the combo pill would be "spray coated",

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ggwpq Member Profile
Member Level 
Followed By 11
Posts 2,329
Boards Moderated 0
Alias Born 09/04/09
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 1/4/2019 4:43:20 PM
Amarin Provides Preliminary 2018 Results and 2019 Outlook GlobeNewswire Inc. - 1/4/2019 4:15:00 PM
Amarin to Present at 37th Annual J.P. Morgan Healthcare Conference on Wednesday, January 9, 2019 GlobeNewswire Inc. - 1/2/2019 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:35:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/30/2018 6:34:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/29/2018 4:08:05 PM
Securities Registration (ads, Immediate) (f-6ef) Edgar (US Regulatory) - 11/29/2018 3:07:20 PM
Amarin to Participate in a Fireside Chat at Citi’s 2018 Global Healthcare Conference GlobeNewswire Inc. - 11/28/2018 6:25:36 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/28/2018 5:24:09 PM
Amarin Prices Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 8:59:19 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 11/26/2018 5:32:33 PM
Amarin Announces Proposed Public Offering of American Depositary Shares GlobeNewswire Inc. - 11/26/2018 4:23:58 PM
Amarin to Present at the Evercore ISI HealthCONx Conference GlobeNewswire Inc. - 11/20/2018 6:00:00 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/14/2018 6:03:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/13/2018 6:18:24 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... PR Newswire (US) - 11/11/2018 10:32:00 AM
Vascepa® (icosapent ethyl) 26% Reduction in Key Secondary Composite Endpoint of Cardiovascular Death, Heart Attacks and Stro... GlobeNewswire Inc. - 11/10/2018 3:00:00 PM
Amarin to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire Inc. - 11/8/2018 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/7/2018 4:13:25 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 11/2/2018 6:12:30 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/1/2018 7:06:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/1/2018 7:05:12 AM
Amarin Reports Third Quarter 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 11/1/2018 5:00:00 AM
Amarin Schedules Webcast Discussion of Primary REDUCE-IT™ Trial Results Following Presentation at 2018 Scientific Sessions ... GlobeNewswire Inc. - 10/26/2018 5:00:00 AM
ggwpq Member Level  Saturday, 01/12/19 11:02:30 AM
Re: SocialBoom post# 171863
Post # of 172906 
Social, the combo pill would be "spray coated", i.e., statin being spray coated outside of Vascepa pill. That shouldn't increase the size of the pill that much as statin pills are small. Following was a Q&A between an analyst and JZ 6 yars ago in an earning CC to shed some light on the combo pill issue:

********************************************

Ritu Baral – Canaccord Genuity, Inc.

Great. And last question, and then I’ll jump back in the queue. Your combination products, have you picked a final formulation for the combination product? And can you confirm that it’s only one statin at a time that you’re going to be moving forward with?

Joseph S. Zakrzewski

Well, I can’t confirm that we have a final formulation. We have a statin or statins picked out. We have the ability to do many things and we still expect to start that study by the end of the year.

Ritu Baral – Canaccord Genuity, Inc.

Any color on the formulation that you picked, whether it’s sort of spray coated capsule like you previously said or…?

Joseph S. Zakrzewski

For competitive reasons, I probably need to lay low on that, Ritu.

Ritu Baral – Canaccord Genuity, Inc.

Fair enough. Thanks guys.

Joseph S. Zakrzewski

Sure.


https://seekingalpha.com/article/792411-amarins-ceo-discusses-q2-2012-results-earnings-call-transcript

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist